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Abstract. Studies were carried out to collimator modelling and dosimetry BNCT of in vitro and in vivo test using 
MCNP-X code. Collimator modelling performed to obtain neutron beam as required by the International Atomic 
Energy Agency (IAEA). Dosimetry calculations performed to obtain the results of the dose calculation (dosimetry) in 
the application of BNCT.  Collimator modelling and dosimetry simulations performed with MCNPX program. Neutron 
sources used for simulation, namely cyclotrons HM-30, energy 30 MeV, the current is 1.1 mA. Collimator modelling 
utilizes to program MCNPX covers cells target as beryllium, collimator wall (reflector), moderate, filter, gamma-ray 
shielding, and aperture. The simulation results of the modelling are Φ
epi 
1.02241x1010 n/cm2 s, D
f
/Φ
epi 
2.36487x10-11 
Gy-cm2/n, D
γ
/Φ
epi
 4.68416x10-12 Gy-cm2/n, Φ
th
/Φ
epi 
3.76285x10-01, J/Φ
epi 
8.37678x103. Based on the calculation of the 
dose rate that has been done, the result that the optimal dose rate at a depth of 1cm.
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INTRODUCTION
Cancer is a group of diseases that cause 
the cells in the body to change and grow out of 
control. Most types of cancer cells eventually 
form a lump or mass called a tumour, and are 
named accordingly part of the body where the 
tumour originated [1]. Breast cancer is one type of 
cancer. Breast cancer cells either spread through 
the bloodstream or the lymphatic system or have 
a predilection to metastasize to certain parts of 
the body such as the lymph nodes, bones, liver, 
lungs, and brain [2]. Breast cancer is the most 
common cause of cancer death among women 
(522,000 deaths in 2012) and the most frequently 
diagnosed cancer among women in 140 of 184 
countries worldwide [3]. Treatment of breast 
cancer, which until now often used are surgery 
and is often combined with other treatments, such 
as radiation therapy, chemotherapy, systemic 
therapy, hormone therapy, and / or targeted 
therapy [1]. Another treatment method for breast 
cancer is brachytherapy. Several methods of 
treatment turned out to have side effects for the 
patient.
Boron Neutron Capture Therapy (BNCT) 
has for many decades been advocated as an 
innovative form of radiotherapy, BNCT has the 
potential to be the ideal form of treatment for 
many types cancer [4]. BNCT is based on the 
nuclear capture and fission reactions that occur 
when the nuclide Boron-10 non-radioactive 
irradiated with thermal neutrons (0.025 eV) 
[5]. 10B absorbs neutrons and produce two 
particles have the Linear Energy Transfer 
(LET) high, α particles (4He) and lithium (7Li) 
[6], [5] for particles of α ≈ 150 keVμm-1 and 
7Li ≈ 175keVμm- 1 [4]. Results of the reaction 
10B (n, α) 7Li has a long-range 6-10μm [7]. 
Neutrons are used in BNCT treatment is thermal 
neutrons and epithermal neutrons. Neutron 
collimator is needed to collimate neutron beam 
[8]. Collimator in BNCT therapy is an important 
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be used to cells target that Beryllium (9Be) 
and lithium (7Li). Materials are selected in 
collimator design under which Beryllium with 
5 cm thick. Beryllium has the advantage of high 
melting point, high thermal conductivity and the 
ability to directly cool the water.
Moderator
Moderator required in BNCT therapy 
should have a high scattering cross section for 
fast neutrons and a low absorption cross section 
for epithermal neutrons. The material used as a 
moderator, Al, Al
2
O
3
, AlF
3
, MgF
2
, PbF
2
, alloy of 
Al / AlF
3
 (30% Al, 70% AlF
3
) and fluent (30% 
Al, 69% AlF
3
, 1% LiF) (Kasesaz, et al., 2014). 
The material used in the collimator, under which 
Al (Aluminium) and Al
2
O
3
 (Aluminium Oxide) 
with a thickness of 2 cm each. 
Filter
Filter the collimator serves to reduce the 
fast neutron component. Cadmium (Cd) is a 
material used as a filter on the design of the 
collimator below 2 cm thick. 
Gamma-ray Shielding
Gamma-ray shielding serves to reduce 
the intensity of the gamma rays produced in the 
collimator. Materials such as Pb, Bi and Ni can be 
used as a shield gamma. Nickel (Ni) thickness of 
5 cm is used in the collimator design below.
Aperture
Aperture is the tip of a conical collimator 
shaped to focus the radiation beam. The size of 
the aperture in the collimator design under that 
thick 5 cm and 6 cm radius.
Wall Collimator (Reflector)
Materials suitable for the reflector are a 
material that has a high scattering cross section 
and has a higher atomic mass. The material used 
part, because the collimator has a function to 
collimate neutrons that come out of the neutron 
source, so that the neutron beam to the patient 
in accordance with predetermined parameters. 
Besides collimator, dosimetry also important 
in BNCT. Dosimetry is the study of various 
magnitudes and unit dose [9]. In the BNCT 
treatment, the dose delivered to the healthy 
and tumour tissues depends on the interaction 
of neutrons with many different nuclei and 
the gamma ray back-ground [10]. Modelling 
collimator and dose calculation is very important 
to test the in vitro and in vivo BNCT therapy. 
Modelling collimator and dose calculations can 
be done using one of the methods of computing, 
namely Monte Carlo. Monte Carlo N-Particle 
(MCNP) code is developed and maintained by 
the Los Alamos National Laboratory [11].
MATERIALS AND METHODS
Collimator Modelling
 Collimator modelling done by using 
MCNP-X. Figure 3.1 shows the geometry used 
in the simulation. Neutron sources used are 30 
MeV cyclotron, which has a specification as 
in table 2.1. The modelling was conducted on 
the part of the target, moderator, filter, shield 
gamma, aperture, and a reflector.
Table 2.1. Main Specification of Cyclotron HM-30 at 
KURRI (12)
Extraction ion Proton
Energy 30 MeV
Current 1,1 mA
Number of extraction port 1
Magnet size 3,0 m (L) x 1,6 m (W) x 
1,7 m (H)
Weight 60 Ons
Cells Target 
Cyclotron is one of neutron source as 
accelerator. Cyclotron change proton particle 
into neutron. Proton into a neutron particle 
changes occur on the target. Materials that can 
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as a reflector in collimator design is graphite 
with a thickness below 20 cm.
Dosimetry
The first stage is define the geometry 
dosimetry calculations used for simulation. 
Geometry used is spherical with a mathematical 
equation as follows:
( ) 02222 =−++− Rzyxx                         (1)
Geometry as the sphere approaches the 
cancerous lump form. Lump is assumed to have 
a shape like a sphere.
The next stage is to determine the material 
making up the tissues, such as H, C, N, O, P, 
Na, P, S, Cl, and K. Tally used to calculate the 
dose is tally f4 by adding a coefficient of Kerma. 
Thus, obtained dose calculation results. The 
final stage in the dosimetry calculations is to 
calculate the total dose rate on each tissue. The 
equation used as follows:  
ggDwDwDwDwD nnppBBTotal
&&&&& +++=
      (2)
Where:
BD
&  :  Dose rate of Boron (Gy/s)
pD
&  :  Dose rate of recoil proton (Gy/s)
nD
&  :  Dose rate of recoil proton (Gy/s)
gD
&  :  Dose rate of gamma (Gy/s)
w
B
 :  radiation weighting factor of alpha, 3.8 
for the tumour tissue and 1.35 for normal 
tissue
w
p
 :  weighting factor of the proton radiation 
is 3.2
w
n
 :  weighting factor of neutron scattering 
radiation is 3.2
w
γ
 :  .
 
RESULTS AND DISCUSSION
Collimator Design
Collimator design simulation results 
using MCNPX program as shown below:
Figure 3.1 Modeling Simulation Results Collimator 
with MCNPX Program
Neutron beam obtained as simulation 
results using MCNPX program are presented 
in Table 3.1.
Based on the results obtained, the value of 
epithermal flux for 1.02241x1010 n/cm2-s IAEA 
has fulfilled recommendation that >1.0x109  n/
cm2-s. Meanwhile, the simulation result for fast 
neutron dose per epithermal flux (Df/Φepi) still 
exceeds the limit recommended values. This is 
possible because the number of fast neutrons 
in the collimator many passes or the number 
Table 3.1 Neutron Beam Collimator Modelling Results with MCNPX Program
Notation
Simulation 
Results
IAEA 
Recommendations
Compliance 
with the IAEA 
recommendations
Φ
epi
 (n/cm2 s) 1.02241x1010 9100.1 ×> Yes
D
f
/Φ
epi
 (Gy-cm2/n) 2.36487x10-11 13100.2 −×< No
D
γ
/Φ
epi
 (Gy-cm2/n) 4.68416x10-12 13100.2 −×< No
Φ
th
/Φ
epi
3.76285x10-01 05.0< No
J/Φ
epi
8.37678x103 7.0>
No (because 
maximum 1)
: 
 
 
 
 
 
 
 
 
 
 
Compliance with 
 
10
 Yes
/n) 
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of fast neutrons in the collimator is still high. 
The simulation results for gamma dose per 
epithermal flux (D
γ
/Φ
epi
) still exceeding the 
standards because of the possible amount of 
radiation in a gamma ray collimator is still 
quite high. The possible numbers of gamma 
rays that pass from gamma shield quite a lot, so 
it is necessary election material and thickness 
settings in the appropriate gamma shield. The 
amount of thermal flux per flux epithermal (Φ
th
/
Φ
epi
) still exceeding the standards for the amount 
of thermal neutrons released by collimator 
fewer than epithermal neutron. Simulation 
results for current ratio per epithermal flux (J/
Φ
epi
) are very far from the value recommended 
by IAEA, possibilities for the direction of the 
neutrons in the collimator is random or not 
mono direction.
Dosimetry
Figure 3.2 Modelling Phantom Breast Cancer
Modelling phantom breast cancer using 
spherical geometry, assuming that the lumps 
(cancer cells) spherical. Phantom is divided 
into several parts, the GTV, CTV, PTV, healthy 
tissue, and skin. Gross tumour volume (GTV) 
Dosimetry 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Modelling Phantom Breast Cancer 
Skin 
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Figure 3.3 Dose rate chart with Boron Concentration (a) 20 μg/g, (b) 25 μg/g, (c) 30 μg/g
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is a measure of how much the cancer visible or 
provable extent or location of the cancer growth. 
Clinical Target Volume (CTV) is a tissue that 
contains GTV has proven malignant disease 
microscopic or sub-clinical to be eliminated. 
Planning Target Volume (PTV) is defined as 
the geometric concepts to radiating volume 
appropriate cancer, in order to ensure that the 
prescribed dose to kill the cancer is absorbed.
Phantom modelling is used to perform 
the calculation of the dose rate. Components of 
the dose in BNCT therapy is dose of neutrons 
scattering, gamma dose, Boron dose (interaction 
of 10B with thermal neutrons), and recoil proton 
dose. Dose of neutrons scattering and gamma 
dose as a result of output collimator can be 
obtained through simulations on MCNPX 
program. While, for the gamma dose, boron 
dose, and the recoil proton dose as results of 
interactions thermal neutron with hydrogen in 
the tissues is done by manual calculation. Dose 
calculation results are presented in Figure 3.3 
The third chart above shows the relationship 
between the depth of the dose rate (dose scattering 
of neutrons, gamma dose, dose boron, and the 
recoil proton dose). Based on the results presented 
in the figure above, all components of the dose 
fluctuation. All the components of the dose began 
to decline when it reaches a depth of 1cm of skin. 
The optimal dose rate only at a depth of 1 cm, 
after it experienced a significant decline. This is 
possible because the probability of the number of 
neutrons reaction with the boron in tissues is less 
than optimal. Thus, the dose rate is only optimal 
when it reaches the organ PTV, not yet to the 
cancer cells. The amount of boron concentration 
and irradiation time is very important in BNCT 
treatment, it is necessary to optimize between 
them. Absorbed dose recommended for BNCT 
therapy was 50 Gy. The result of dosimetry 
calculations can not be used for in vitro and in 
vivo in application of BNCT.
CONCLUSION AND REMARKS
CONCLUSION
Modelling collimator using cyclotron 30 
MeV neutron source. The modelling includes 
parts of the target cell, a moderator, filter, shield 
gamma, reflectors, and aperture. MCNPX 
simulation results show that the epithermal neutron 
flux issued by the collimator has met standard 
IAEA is equal 1.02241x1010 n/cm2-s. Dose rate 
calculation performed on the four components of 
the therapeutic dose BNCT. Boron concentrations 
used in the simulation are 20 μg/g, 25 μg/g, and 
30 μg/g. Based on calculations, the optimal dose 
rate at a depth of 1 cm.
Remarks
Need to do further research relate to 
modelling collimator and dosimetry calculations, 
in order to obtain results in accordance with the 
parameters.
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